Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK),
known as MSD outside the United States and Canada, today announced that
the New England Journal of Medicine published the results
of the IMPROVE-IT trial, an investigational study comparing treatment
with VYTORIN (ezetimibe and simvastatin) to treatment with
simvastatin alone in more than 18,000 patients presenting with acute
coronary syndromes.
Language:
English
Contact:
MerckMedia:Pamela Eisele, (267) 305-3558Tracy Ogden, (267) 305-2301orInvestor:Justin Holko, (908) 740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more